Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.50 |
| ▸ | CTSS | P25774 | 7/20 | 0.50 |
| ▸ | CTSL | P07711 | 5/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21885556 | 0.86 | CTSK (0.63) | CTSKCTSSCTSLCTSBPOLB | |
| SCHEMBL18154376 | 0.86 | CTSK (0.63) | CTSKCTSSCTSLCTSBPOLB | |
| SCHEMBL21428920 | 0.82 | CTSK (0.58) | CTSKCTSSCTSLCTSBPOLB | |
| SCHEMBL23446167 | 0.81 | REN (0.64) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL9038435 | 0.80 | CTSK (0.61) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL10904441 | 0.78 | CTSK (0.69) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL21430242 | 0.77 | CYP1A2 (0.46) | CTSKCTSSCTSLCTSBPOLB | |
| SCHEMBL11033975 | 0.76 | CTSS (0.58) | CTSKCTSSCTSLCTSBKLK7 | |
| SCHEMBL11123304 | 0.76 | CTSS (0.69) | CTSKCTSSCTSLCTSB | |
| SCHEMBL25283632 | 0.76 | CTSK (0.76) | CTSKCTSSCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713339-B2 | Macrocyclization of peptidomimetics | UNIVERSITY OF WARWICK (GB) | 2023-08-01 | — | — | US | disclosed |
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2021-01-28 | — | — | US | disclosed |
| WO-2019186174-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | UNIVERSITY OF WARWICK (GB) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024579-A1 | MACROCYCLIZATION OF PEPTIDOMIMETICS | NGLY1, MAX, VIP | CTSK 1350/4885CTSS 1471/4885CTSL 769/4885 |
| US-11713339-B2 | Macrocyclization of peptidomimetics | NGLY1, MAX, PTMA | CTSK 528/4885CTSS 666/4885CTSL 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.